Article Details
Retrieved on: 2025-02-05 15:30:07
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses PDS Biotechnology's deeptech advancements in cancer immunotherapy, focusing on the upcoming Phase 3 trial of Versamune® HPV with pembrolizumab for HPV16-positive head and neck cancer, highlighting EMV Capital's investment involvement.
Article found on: www.investegate.co.uk
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here